SAN DIEGO--(BUSINESS WIRE)--Biocom, the association representing the California life science industry, today announced the appointment of two new members to its board of directors: Deanne Calvert, J.D., head of state government relations for Sanofi US, and Ranjeet Banerjee, worldwide president of Medication Management Solutions for BD, a leading global medical technology company. Ms. Calvert will be replacing the board position of Gregory Fond, director of strategy, science policy & external innovation at Sanofi. In addition, Biocom announced that current board member Steven Pacelli, executive vice president of strategy & corporate development at Dexcom, will also join the executive committee.
“Ms. Calvert and Mr. Banerjee’s specific and comprehensive skillsets in government relations and medical device business operations and driving new medical technology and informatics innovations to market, respectively, are invaluable additions to Biocom’s board of directors, and Steve has made great contributions to our board already,” said Joe Panetta, president and CEO of Biocom. “They will bring diverse points of view that will help inform Biocom’s strategic growth as we serve our more than 1,100 members across the state of California.”
Deanne Calvert is head of state government relations for Sanofi US. Ms. Calvert has worked in the state legislative environment for over twenty years. Her career began as staff to the Washington Senate, before she founded a Washington State legislative counsel practice in the Seattle office of APCO Public Affairs, where she served as vice president. She joined Sanofi in 2001 to lead its West Coast government affairs region. In 2018, she was appointed to her current role as head of State Government Relations in the United States. Deanne graduated with a bachelor of arts in international relations magna cum laude from the University of San Diego and a J.D. from University of Notre Dame Law School (after attending the Concannon Program of International Law in London, UK).
“With its culture of innovation and deep biotechnology history, California is a national leader in the industry,” said Ms. Calvert. “I am grateful for the opportunity to work with Biocom to further its goals and to enhance the opportunities for biotechnology initiatives in the state.”
Ranjeet Banerjee is the worldwide president of the Medication Management Solutions (MMS) business unit for BD. Mr. Banerjee began his career with BD in 1995 as a plant manager and was responsible for the start-up of the BD India plant. In January 2001, he relocated to Singapore, serving as the director of operations for BD Asia Pacific, and in July 2003 took on the role of vice president of global operations for BD Medical – Medical Surgical Systems. In October 2013, Mr. Banerjee assumed the role of worldwide president of BD Medical – Diabetes Care. He moved into his current role in January 2015 and is a member of the BD Medical segment leadership team. He served on the leadership advisory council of the Joint Commission's Center for Transforming Healthcare (2013-2014). Prior to joining BD, Mr. Banerjee was with Unilever, India for nine years in various management positions. He holds a bachelor of technology in chemical engineering from the Indian Institute of Technology (IIT), Kanpur, India. He serves on the board of directors for the California Life Sciences Association and the San Diego Regional Economic Development Corporation.
“It is a privilege to be named to Biocom’s board of directors, and I look forward to helping shape the association as it aims to accelerate the development of cutting-edge innovations and drive public policy that will help the life sciences economy grow in the San Diego region and across California,” said Mr. Banerjee. “It is an honor to be selected to the board of an organization committed to driving medical technology solutions that improve the human condition and is very much aligned with our company purpose of advancing the world of health.”
Biocom is the largest, most experienced leader and advocate for California’s life science sector. We work on behalf of more than 1,100 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.
Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom operates core offices in Los Angeles and the San Francisco Bay Area, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.